K Number
K981580
Device Name
HDL
Date Cleared
1998-06-11

(38 days)

Product Code
Regulation Number
862.1475
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdparty
Intended Use
The Direct HDL assay is used for the quantitation of high-density lipoprotein cholesterol levels in human serum or plasma. Low Direct HDL measurements are used in the diagnosis and treatment of coronary artery disease.
Device Description
Direct HDL is an in vitro diagnostic assay for the quantitative determination of high-density lipoprotein cholesterol in serum or plasma. The Direct HDL assay is a two reagent format and depends on the properties of a unique detergent. This detergent solubilizes only the HDL lipoprotein particles, thus releasing the HDL cholesterol to react with cholesterol esterase and cholesterol oxidase, in the presence of chromogens to produce color. In addition to selectively disrupting the HDL lipoprotein particles, this unique detergent also inhibits the reaction of the cholesterol enzymes with LDL, VLDL, and chylomicron lipoproteins by adsorbing to their surfaces. A polyanion is contained in the first reagent to assist with complexing LDL, VLDL, and chylomicron lipoproteins, further enhancing the selectivity of the detergent and enzymes for HDL cholesterol.
More Information

Not Found

No
The device description details a chemical assay based on enzymatic reactions and selective detergents, with no mention of computational analysis, algorithms, or learning processes. The performance studies focus on standard analytical metrics like correlation, precision, and linearity, not AI/ML performance metrics.

No
The device is described as an "in vitro diagnostic assay" used for the quantitative determination of high-density lipoprotein cholesterol levels to aid in diagnosis and treatment, not to provide therapy itself.

Yes
The "Intended Use / Indications for Use" section states, "Low Direct HDL measurements are used in the diagnosis and treatment of coronary artery disease." This indicates that the device provides information used for diagnosis.

No

The device description clearly indicates it is an in vitro diagnostic assay involving chemical reagents and reactions to measure HDL levels, which is a hardware-based process.

Yes, this device is an IVD (In Vitro Diagnostic).

Here's why:

  • Intended Use: The "Intended Use / Indications for Use" section explicitly states that the assay is used for the quantitation of HDL cholesterol levels in human serum or plasma, and that these measurements are used in the diagnosis and treatment of coronary artery disease. This clearly indicates a diagnostic purpose.
  • Device Description: The "Device Description" further clarifies that it is an "in vitro diagnostic assay" for the quantitative determination of HDL cholesterol in serum or plasma. The description of the chemical process involved in analyzing the sample also aligns with the nature of an in vitro diagnostic test.
  • Predicate Device: The mention of a "Predicate Device" (K963213 Boehringer Mannheim® Direct HDL-Cholesterol assay) which is also an IVD, strongly suggests that this device falls into the same category.

The information provided clearly defines the device as a test performed on biological samples (serum or plasma) outside of the body (in vitro) to provide information for diagnostic purposes.

N/A

Intended Use / Indications for Use

The Direct HDL assay is used for the quantitation of high-density lipoprotein cholesterol in serum or plasma.

The Direct HDL assay is used for the quantitation of high-density lipoprotein cholesterol levels in human serum or plasma. Low Direct HDL measurements are used in the diagnosis and treatment of coronary artery disease.

Product codes (comma separated list FDA assigned to the subject device)

75LBS

Device Description

Direct HDL is an in vitro diagnostic assay for the quantitative determination of high-density lipoprotein cholesterol in serum or plasma. The Direct HDL assay is a two reagent format and depends on the properties of a unique detergent. This detergent solubilizes only the HDL lipoprotein particles, thus releasing the HDL cholesterol to react with cholesterol esterase and cholesterol oxidase, in the presence of chromogens to produce color. In addition to selectively disrupting the HDL lipoprotein particles, this unique detergent also inhibits the reaction of the cholesterol enzymes with LDL, VLDL, and chylomicron lipoproteins by adsorbing to their surfaces. A polyanion is contained in the first reagent to assist with complexing LDL, VLDL, and chylomicron lipoproteins, further enhancing the selectivity of the detergent and enzymes for HDL cholesterol.

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

Not Found

Indicated Patient Age Range

Not Found

Intended User / Care Setting

Not Found

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

Comparative performance studies were conducted using the AEROSET™ System. The Direct HDL assay method comparison yielded acceptable correlation with the Boehringer Mannheim Direct HDL-Cholesterol assay on the Hitachi 717 Analyzer. The correlation coefficient = 0.9883, slope =1.041, and Y-intercept =0.118 mg/dL. Precision studies were conducted using the Direct HDL assay. Within-run, between-run, and between-day studies were performed using two levels of control material. The total %CV for Level 1/Panel 109 is 5.3% and Level 2/Panel 110 is 3.3%. The Direct HDL assay is linear up to 309.6 mg/dL. The limit of quantititation (sensitivity) of the Direct HDL assay is 1.2 mg/dL. These data demonstrate that the performance of the Direct HDL assay is substantially equivalent to the performance of the Boehringer Mannheim Direct HDL-Cholesterol assay on the Hitachi 717 Analyzer.

Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)

The correlation coefficient = 0.9883, slope =1.041, and Y-intercept =0.118 mg/dL. The total %CV for Level 1/Panel 109 is 5.3% and Level 2/Panel 110 is 3.3%. The Direct HDL assay is linear up to 309.6 mg/dL. The limit of quantititation (sensitivity) of the Direct HDL assay is 1.2 mg/dL.

Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.

K963213

Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).

Not Found

§ 862.1475 Lipoprotein test system.

(a)
Identification. A lipoprotein test system is a device intended to measure lipoprotein in serum and plasma. Lipoprotein measurements are used in the diagnosis and treatment of lipid disorders (such as diabetes mellitus), atherosclerosis, and various liver and renal diseases.(b)
Classification. Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 862.9.

0

JUN 11 1998

K981/580

510(k) Summary

Submitter's Name/Address

Abbott Laboratories 1920 Hurd Drive Irving, Texas 75038 Contact Person Mark Littlefield Section Manager MS 1-8 ADD Regulatory Affairs 972) 518-6062 Fax (972) 753-3367

Date of Preparation of this Summary:May 1, 1998
Device Trade or Proprietary Name:HDL
Device Common/Usual Name or Classification Name:Direct HDL
Classification Number/Class:75LBS /Class I

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

The assigned 510(k) number is:

Test Description:

Direct HDL is an in vitro diagnostic assay for the quantitative determination of high-density lipoprotein cholesterol in serum or plasma. The Direct HDL assay is a two reagent format and depends on the properties of a unique detergent. This detergent solubilizes only the HDL lipoprotein particles, thus releasing the HDL cholesterol to react with cholesterol esterase and cholesterol oxidase, in the presence of chromogens to produce color. In addition to selectively disrupting the HDL lipoprotein particles, this unique detergent also inhibits the reaction of the cholesterol enzymes with LDL, VLDL, and chylomicron lipoproteins by adsorbing to their surfaces. A polyanion is contained in the first reagent to assist with complexing LDL, VLDL, and chylomicron lipoproteins, further enhancing the selectivity of the detergent and enzymes for HDL cholesterol.

Direct HDL 510(k) May 1, 1998 Aero HDLf.lwp

Section II Page 1

0000012

1

Substantial Equivalence:

The Direct HDL assay is substantially equivalent to the Boehringer Mannheim® Direct HDL-Cholesterol assay (K963213) on the Hitachi® 717 Analyzer. These assays yield similar Performance Characteristics.

Similarities:

  • Both assays are in vitro clinical chemistry methods. .
  • Both assays can be used for the quantitative determination of Direct HDL. .
  • Both assays yield similar clinical results. .

Differences:

  • There is a difference between the assay range. .

Intended Use:

The Direct HDL assay is used for the quantitation of high-density lipoprotein cholesterol in serum or plasma.

Performance Characteristics:

Comparative performance studies were conducted using the AEROSET™ System. The Direct HDL assay method comparison yielded acceptable correlation with the Boehringer Mannheim Direct HDL-Cholesterol assay on the Hitachi 717 Analyzer. The correlation coefficient = 0.9883, slope =1.041, and Y-intercept =0.118 mg/dL. Precision studies were conducted using the Direct HDL assay. Within-run, between-run, and between-day studies were performed using two levels of control material. The total %CV for Level 1/Panel 109 is 5.3% and Level 2/Panel 110 is 3.3%. The Direct HDL assay is linear up to 309.6 mg/dL. The limit of quantititation (sensitivity) of the Direct HDL assay is 1.2 mg/dL. These data demonstrate that the performance of the Direct HDL assay is substantially equivalent to the performance of the Boehringer Mannheim Direct HDL-Cholesterol assay on the Hitachi 717 Analyzer.

Direct HDL 510(k) May 1, 1998 Aero HDLf.lwp

Section II Page 2

0000013

2

Conclusion:

College Commend Comments of Children

1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1

The Direct HDL assay is substantially equivalent to the Boehringer Mannheim Direct HDL-Cholesterol assay on the Hitachi 717 Analyzer as demonstrated by results obtained in the studies.

Direct HDL 510(k)
May 1, 1998
Aero HDLf.lwp

Section II Page 3

  1. . . .

ﺍﻟﺴﻌﻮﺩﻳﺴﻤﻴﺔ ﻭﺳﻤﺘﻨﺘﻬﻢ ﻣﻨﺘﺨﺒﺎﺕ ﻣﺘﺮﻭ ﻣﺘﺮﻭﺑﻴﻦ

0000014

3

Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized depiction of an eagle or bird-like figure, rendered in black, with flowing lines suggesting movement or flight. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" are arranged in a circular fashion around the bird symbol.

JUN 11 1998

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

Mark Littlefield · Section Manager, Regulatory Affairs Abbott Laboratories 1920 Hurd Drive Irving, Texas 75038

Re : K981580 Direct HDL Requlatory Class: I Product Code: LBS Dated: May 1, 1998 Received: May 4, 1998

Dear Mr. Littlefield:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labelinq, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Druq Administration (FDA) will verify such assumptions. Failure to comply with the GMP requlation may result in requlatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

4

Page 2

Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.

This letter will allow you to begin marketing your device as described in your 510 (k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".

Sincerely yours,
Steven Litman

Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

5

510(k) Number (if known):

Direct HDL Device Name:

Indications For Use:

The Direct HDL assay is used for the quantitation of high-density lipoprotein cholesterol levels in human serum or plasma. Low Direct HDL measurements are used in the diagnosis and treatment of coronary artery disease.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use (Per 21 CFR 801.109) (Optional Format 1-2-96)

OR

Over-The-Counter Use

00000006

सम

(Division
Division
510(k) Number K984580